Abstract This Consensus Statement from an international, multidisciplinary workshop
sponsored by the Pituitary Society offers evidence-based graded consensus …

The tumor microenvironment (TME), the complex environment in which tumors develop, has
been increasingly targeted for cancer treatment in recent years. Aggressive pituitary tumors …

The pituitary tumour microenvironment encompasses a spectrum of non-tumoural cells, such
as immune, stromal or endothelial cells, as well as enzymes and signalling peptides like …

Immunotherapy has revolutionised the treatment of oncological patients, but its application
in various endocrine tumours is rather limited and is mainly used when conventional …

Simple Summary Pituitary adenomas are highly prevalent intracranial neoplasms that can
be locally invasive in up to half of cases. Consequently, using the term “PitNETs”(pituitary …

Pituitary neuroendocrine tumors (PitNETs) are the most common pituitary tumors and the
second most common brain tumors. Although the vast majority (> 90%) are benign, a small …

Introduction Refractory pituitary adenomas are those that have progressed following
standard of care treatments. Medical therapy options for these challenging tumors are …

Pituitary neuroendocrine tumors (pitNETs) are the second most common primary brain
tumors. Despite their prevalence, the tumor immune microenvironment (TIME) and its clinical …

Purpose Predicting resistance to first-generation Somatostatin Receptor Ligands (fg-SRL) in
Acromegaly patients remains an ongong challenge. Tumor-associated immune components …

Conclusions An enlarged panel of effective drugs available with increased knowledge of
predictive factors for response and/or adverse effects will enhance the possibility to offer a …